Diagnosis and Treatment of P-ANCA Associated Vasculitis

Diagnostic Significance of P-ANCA

P-ANCA is detected through indirect immunofluorescence (IIF) testing and should be confirmed with specific enzyme-linked immunosorbent assays (ELISA) for myeloperoxidase (MPO), which is the main target antigen in P-ANCA positive vasculitis, according to the American College of Rheumatology 1
P-ANCA positivity is detected in 30-40% of patients with eosinophilic granulomatosis with polyangiitis (EGPA), with most of these patients testing positive for MPO-ANCA specifically, as reported by the European League Against Rheumatism 2, 3
Approximately 5% of granulomatosis with polyangiitis (GPA) patients can also have a positive P-ANCA/MPO, highlighting the importance of differential diagnosis, according to the American College of Rheumatology 1, 4

P-ANCA can be found in various conditions beyond vasculitis, including autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease, as noted by the American Gastroenterological Association 2, 5, 6
The clinical phenotype associated with MPO-ANCA positivity in vasculitis typically includes glomerulonephritis, peripheral neuropathy, and purpura, according to the National Kidney Foundation 2, 3, 7

For suspected vasculitis, perform both IIF for ANCA pattern determination and ELISA for specific antigens (MPO and PR3), as recommended by the American College of Rheumatology 1, 7
A positive P-ANCA test should always be followed by MPO-ANCA testing for confirmation, according to the European League Against Rheumatism 2

Regular clinical assessment for disease activity is crucial in managing P-ANCA associated vasculitis, as emphasized by the American College of Rheumatology 1
Patients with rapidly deteriorating renal function or pulmonary hemorrhage with positive MPO-ANCA require prompt treatment, without delay for biopsy confirmation, according to the National Kidney Foundation 7, 8

Patients with ANCA-positive vasculitis tend to have more frequent relapses than ANCA-negative patients, requiring vigilant monitoring, as noted by the European League Against Rheumatism 2
Comorbidity management, including prophylaxis against treatment-related complications and cardiovascular risk management, is essential in patients with P-ANCA associated vasculitis, according to the American Heart Association 3

ANCA status has prognostic implications - in EGPA, overall survival appears worse in ANCA-negative patients, while relapses tend to be more frequent in ANCA-positive patients, as reported by the European League Against Rheumatism 2
Sequential monitoring of ANCA titers can be useful in predicting relapse in some patients, though not all show this pattern, according to the American College of Rheumatology 1